ARTICLE | Clinical News
JZP-110: Phase III started
June 29, 2015 7:00 AM UTC
Jazz began the double-blind, placebo-controlled, North American Phase III Study 14-002 to evaluate 75, 150 and 300 mg oral JZP-110 for 12 weeks in about 240 adult patients. Patients may be eligible to...